Insilico Medicine and SK Biopharmaceuticals agreed on an AI-based neuroimmune drug discovery collaboration that could generate up to $2.5 billion. Insilico will apply its Pharma.AI platform covering target validation, generative chemistry, and molecule optimization, while SK will provide development and clinical capabilities for resulting neuroimmune programs and steer commercialization. The agreement underscores how major CNS-focused companies are turning to AI-enabled discovery engines to accelerate candidate generation, while keeping late-stage execution in-house. Insilico’s role is framed as taking programs to a defined preclinical point before SK exercises options. For the market, the deal signals continued allocation to “AI-to-candidate” workflows, particularly in complex neuroimmune indications where biology is often difficult and attrition risk is high.